



Drugs and Drug Delivery for Diabetes Mellitus Treatment

Guest Editors:

Prof. Dr. Laurent Kodjikian

Department of Ophthalmology,
Croix-Rousse University Hospital,
Hospices Civils de Lyon,
University of Lyon 1, 69004 Lyon,
France

Dr. Thibaud Mathis

Department of Ophthalmology,
Croix-Rousse University Hospital,
Hospices Civils de Lyon,
University of Lyon 1, 69004 Lyon,
France

Deadline for manuscript
submissions:

closed (10 May 2023)

Message from the Guest Editors

Diabetes is an epidemic disease with a prevalence that will double over the next 20 years. Diabetic macular oedema is the main cause of visual impairment in young people under 50. Screening for diabetic retinopathy is essential and is increasingly helped by artificial intelligence. The classification of diabetic retinopathy is now quite old and must evolve, particularly with the help of OCT. Diagnosis has become multimodal. As for treatments, they are numerous, from anti-VEGF to steroids, with short- or long-acting molecules.

This Special Issue of the *Pharmaceutics* journal to be quite open about the ophthalmological damage of diabetes, from diabetic retinopathy to diabetic macular oedema, more specifically dedicated to its therapeutic management. Indeed, I would like to receive original articles about new molecules with new drug molecular structures, new pathways of action, new mechanisms of action, new combination therapies or even biosimilars. Articles on short, medium or long delivery systems, such as implants, are welcome, especially on steroids, which are classical in DME management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of
Pharmacy, Rutgers, The State
University of New Jersey, William
Levine Hall, Room 225C, 160
Frelinghuysen Road, Piscataway,
NJ 08854-8020, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma